COBRA - Chemoablation for Low Grade Bladder Cancer: A single arm, prospective, open-label, investigator-initiated Phase 2 study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517106-28-00

Enrollment

Registered

2024-10-30

Start date

2023-12-27

Completion date

Unknown

Last updated

2024-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer

Brief summary

Clinical complete response (cCR, absence of the macroscopic tumor after chemoablation)

Detailed description

Pathological complete response (pCR), Overall response (cCR + pCR), Treatment-related adverse events evaluated using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 5.0), Rate of treatment discontinuation (at least 5 from 6 instillations within 8 weeks), Health-related quality of life

Interventions

DRUGGEMSOL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Clinical complete response (cCR, absence of the macroscopic tumor after chemoablation)	—

Secondary

Measure	Time frame
Pathological complete response (pCR), Overall response (cCR + pCR), Treatment-related adverse events evaluated using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 5.0), Rate of treatment discontinuation (at least 5 from 6 instillations within 8 weeks), Health-related quality of life	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026